作者
Paula Rodríguez-Márquez,María Eréndira Calleja-Cervantes,Guillermo Serrano,Aina Oliver‐Caldés,María Luisa Palacios-Berraquero,Ángel Martín-Mallo,Cristina Calviño,Marta Español‐Rego,Candela Ceballos,Teresa Lozano,Patxi San Martín-Úriz,Amaia Vilas‐Zornoza,Saray Rodríguez-Díaz,Rebeca Martínez-Turrillas,Patricia Jáuregui,Diego Alignani,María C. Viguria,Margarita Redondo,Mariona Pascal,Manel Juan,Álvaro Urbano‐Ispizua,Paula Rodríguez‐Otero,Ana Alfonso Piérola,Bruno Paiva,Juan José Lasarte,Susana Inogés,Ascensión López‐Díaz de Cerio,Jesús F. San Miguel,Carlos Fernández de Larrea,Mikel Hernáez,Juan R. Rodriguez‐Madoz,Felipe Prósper
摘要
ABSTRACT Identification of new markers associated with long-term efficacy in patients treated with CAR T cells is a current medical need, particularly in diseases such as multiple myeloma. In this study we address the impact of CAR density on the functionality of BCMA-CAR T cells. Functional and transcriptional studies demonstrate that CAR T cells with high expression of the CAR construct show an increased tonic signaling with upregulation of exhaustion markers, increased in vitro cytotoxicity but a decrease in in vivo BM infiltration. Characterization of Gene Regulatory Networks using scRNA-seq identified regulons associated to activation and exhaustion upregulated in CAR High T cells, providing mechanistic insights behind differential functionality of these cells. Finally, we demonstrate that patients treated with CAR T cell products enriched in CAR High T cells show a significantly worse clinical response in several hematological malignancies. In summary, our work demonstrates that CAR density plays an important role in CAR T activity with significant impact on clinical response. Teaser High CAR molecule density affects CAR T cell activity and associates with impaired clinical response.